Lakewood-Amedex Biotherapeutics Inc. (LABT) Starts Phase 2a Dosing for Nu-3; Data Expected Q1 2027

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers. The study tests 2%, 5%, and 10% gel concentrations, with topline data expected in Q1 2027.Material DetailsContext by AI AnalystThis is an early-to-mid clinical milestone for…